Literature DB >> 181122

Postoperative radiation therapy for residual Wilm's tumor. Review of Group III patients in the National Wilm's Tumor Study.

M Tefft, G J D'Angio, W Grant.   

Abstract

Fifty-eight patients with residual abdominal disease (Group III) are reviewed from National Wilm's Tumor Study "1. The totap III) are reviewed from National Wilm's Tumor Study No. 1. The total number of abdominal recurrences is relatively low (eight cases). Local irradiation of the renal fossa would seem to be sufficient treatment for disease believed to be limited to that region, including cases of local spillage. Whole abdominal irradiation is recommended for gross, diffuse peritoneal contamination.

Entities:  

Mesh:

Year:  1976        PMID: 181122     DOI: 10.1002/1097-0142(197606)37:6<2768::aid-cncr2820370630>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Outcomes of children with favorable histology wilms tumor and peritoneal implants treated in National Wilms Tumor Studies-4 and -5.

Authors:  John A Kalapurakal; Daniel M Green; Gerald Haase; James R Anderson; Jeffrey S Dome; Paul E Grundy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-01       Impact factor: 7.038

2.  Treatment of Wilms' tumor in children.

Authors:  D G Johnson
Journal:  World J Surg       Date:  1980-01       Impact factor: 3.352

3.  Management of Wilms' tumor and neuroblastoma.

Authors:  P Mehta; T Vats
Journal:  Indian J Pediatr       Date:  1981 Jul-Aug       Impact factor: 1.967

4.  Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.

Authors:  Andrew D Woods; Noah E Berlow; Michael V Ortiz; Filemon Dela Cruz; Armaan Siddiquee; Diego F Coutinho; Reshma Purohit; Katherine E Tranbarger Freier; Joel E Michalek; Melvin Lathara; Kevin Matlock; Ganapati Srivivasa; Brigitte Royer-Pokora; Renata Veselska; Andrew L Kung; Charles Keller
Journal:  Pediatr Blood Cancer       Date:  2021-10-24       Impact factor: 3.838

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.